English
Back
Open Account
牛牛名人追蹤
wrote a column · ·

Tracking Cathie Wood: Massive sell-off in biotech innovation stocks, reducing RXRX holdings by over 1.66 million shares

On Thursday, all three major U.S. stock indices surged sharply. The S&P 500 rose 1.75% to close at 7,394.30 points, the Nasdaq jumped 2.54% to 25,809.66 points, and the Dow Jones climbed 1.86% to 50,848.75 points. Market sentiment clearly warmed, with technology stocks once again leading the rally.
On Thursday, all three major U.S. stock indices surged sharply. The S&P 500 rose 1.75% to close at 7,394.30 points, the Nasdaq jumped 2.54% to 25,809.66 points, and the Dow Jones climbed 1.86% to 50,848.75 points. Market sentiment clearly warmed, with technology stocks once again leading the rally. Against this backdrop, Cathie Wood chose to significantly reduce holdings across multiple innovative names, reflecting a potential deep portfolio rebalancing—possibly driven by strategic considerations around liquidity management and position reallocation. Selling activity: Large-scale reduction in innovative healthcare and emerging tech positions Cathie Wood made no new purchases that day but executed substantial reductions across 20 holdings, with the heaviest concentration in biotechnology and innovative healthcare sectors. The largest reduction was in$Recursion Pharmaceuticals (RXRX.US)$, with 1.6657 million shares sold. The company specializes in an AI-driven drug discovery platform. Next was the flying car concept stock$Archer Aviation (ACHR.US)$, with 1.337 million shares sold. Medical device company$Cerus (CERS.US)$was also reduced by 540,800 shares. In the fields of gene sequencing and precision medicine, Cathie Wood reduced her holdings$Twist Bioscience (TWST.US)$417,600 shares,$Pacific Biosciences of California (PACB.US)$393,000 shares, ...
Against this backdrop, Cathie Wood chose to significantly reduce holdings across multiple innovative names, reflecting a potential deep portfolio rebalancing—possibly driven by strategic considerations around liquidity management and position reallocation.
Selling activity: Large-scale reduction in innovative healthcare and emerging tech positions
Cathie Wood made no new purchases that day but executed substantial reductions across 20 holdings, with the heaviest concentration in biotechnology and innovative healthcare sectors.
The largest reduction was in$Recursion Pharmaceuticals (RXRX.US)$, with 1.6657 million shares sold. The company specializes in an AI-driven drug discovery platform. Next was the flying car concept stock$Archer Aviation (ACHR.US)$, with 1.337 million shares sold. Medical device company$Cerus (CERS.US)$was also reduced by 540,800 shares.
In the fields of gene sequencing and precision medicine, Cathie Wood reduced her holdings$Twist Bioscience (TWST.US)$417,600 shares,$Pacific Biosciences of California (PACB.US)$393,000 shares,$10x Genomics (TXG.US)$263,100 shares, among other positions. These companies are all representative 'disruptive innovation' enterprises that she has long been bullish on.
Notably, Cathie Wood also reduced holdings of$Baidu (BIDU.US)$64,900 shares,$Robinhood (HOOD.US)$167,700 shares,$Roku Inc (ROKU.US)$97,600 shares.
Such large-scale reductions may reflect multiple considerations. First, selling into a strong market rally could be a classic liquidity management strategy—trimming positions when prices rise. Second, ARK may be adjusting its portfolio concentration, lowering the weight of individual holdings to achieve better risk diversification. Additionally, as innovation-driven sectors diverge in their development trajectories, Cathie Wood might be reallocating capital—exiting weaker positions to preserve strength and focusing funds on the most promising growth opportunities.
Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!
On Thursday, all three major U.S. stock indices surged sharply. The S&P 500 rose 1.75% to close at 7,394.30 points, the Nasdaq jumped 2.54% to 25,809.66 points, and the Dow Jones climbed 1.86% to 50,848.75 points. Market sentiment clearly warmed, with technology stocks once again leading the rally. Against this backdrop, Cathie Wood chose to significantly reduce holdings across multiple innovative names, reflecting a potential deep portfolio rebalancing—possibly driven by strategic considerations around liquidity management and position reallocation. Selling activity: Large-scale reduction in innovative healthcare and emerging tech positions Cathie Wood made no new purchases that day but executed substantial reductions across 20 holdings, with the heaviest concentration in biotechnology and innovative healthcare sectors. The largest reduction was in$Recursion Pharmaceuticals (RXRX.US)$, with 1.6657 million shares sold. The company specializes in an AI-driven drug discovery platform. Next was the flying car concept stock$Archer Aviation (ACHR.US)$, with 1.337 million shares sold. Medical device company$Cerus (CERS.US)$was also reduced by 540,800 shares. In the fields of gene sequencing and precision medicine, Cathie Wood reduced her holdings$Twist Bioscience (TWST.US)$417,600 shares,$Pacific Biosciences of California (PACB.US)$393,000 shares, ...
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
5
Lol
2
118K Views
Report
Comments (10)
Write a Comment...
10
7
6